Furthermore, the treatment of silybin could alleviate NAFLD in FaO liver cells by increasing the expression of PPAR-α/δ and decreasing the expression of PPAR-γ [138]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.